Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up.

[1]  Frederic S. Resnic,et al.  Long-Term Clinical Outcomes After Drug-Eluting and Bare-Metal Stenting in Massachusetts , 2008, Circulation.

[2]  S. Normand,et al.  Drug-eluting or bare-metal stents for acute myocardial infarction. , 2008, The New England journal of medicine.

[3]  Deepak L. Bhatt,et al.  Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis , 2008, The Lancet.

[4]  Deepak L. Bhatt,et al.  The effect of drug-eluting stents on intermediate angiographic and clinical outcomes in diabetic patients: insights from randomized clinical trials. , 2008, American heart journal.

[5]  H. Putter,et al.  Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. , 2008, Journal of the American College of Cardiology.

[6]  W. Little,et al.  "Off-label" stent therapy 2-year comparison of drug-eluting versus bare-metal stents. , 2008, Journal of the American College of Cardiology.

[7]  R. Wilensky,et al.  A comparison of bare-metal and drug-eluting stents for off-label indications. , 2008, The New England journal of medicine.

[8]  John Bresnahan,et al.  Outcomes of Stent Thrombosis and Restenosis During Extended Follow-Up of Patients Treated With Bare-Metal Coronary Stents , 2007, Circulation.

[9]  A. Maresta,et al.  Abstract 2148: Sirolimus-eluting Stent Versus Bare-metal Stent In Diabetic Patients: Results Of The Italian Multicenter, Randomized "Dessert" Study. , 2007 .

[10]  T. Wichter,et al.  Abstract 2150: A European and Canadian Multicenter Randomized, Double-Blind Trial of the Sirolimus-Eluting Stent (SES) in Patients with De Novo Native Coronary Artery Lesions (NEW-SIRIUS): 5-Year Clinical Outcomes , 2007 .

[11]  H. Drexler,et al.  One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients. , 2007, Journal of the American College of Cardiology.

[12]  Patrick W Serruys,et al.  Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. , 2007, Journal of the American College of Cardiology.

[13]  Simon Wandel,et al.  Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis , 2007, The Lancet.

[14]  M. Hori,et al.  Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents , 2007, Circulation.

[15]  A. Erglis,et al.  A randomized comparison of paclitaxel-eluting stents versus bare-metal stents for treatment of unprotected left main coronary artery stenosis. , 2007, Journal of the American College of Cardiology.

[16]  G. Biondi Zoccai,et al.  Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). , 2007, Journal of interventional cardiology.

[17]  R. Ferrari,et al.  Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. , 2007, Journal of the American College of Cardiology.

[18]  Ángel Martínez,et al.  Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. , 2007, American heart journal.

[19]  Antonio Colombo,et al.  Offsetting Impact of Thrombosis and Restenosis on the Occurrence of Death and Myocardial Infarction After Paclitaxel-Eluting and Bare Metal Stent Implantation , 2007, Circulation.

[20]  Hong-Bing Yan,et al.  Firebird sirolimus eluting stent versus bare mental stent in patients with ST-segment elevation myocardial infarction. , 2007, Chinese medical journal.

[21]  Arianna Azzellino,et al.  Randomized trial of Sirolimus-Eluting Stent Versus Bare-Metal Stent in Acute Myocardial Infarction (SESAMI). , 2007, Journal of the American College of Cardiology.

[22]  P. Serruys,et al.  Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). , 2007, The American journal of cardiology.

[23]  D. Berman,et al.  Optimal medical therapy with or without PCI for stable coronary disease. , 2007, The New England journal of medicine.

[24]  Johan Lindbäck,et al.  Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. , 2007, The New England journal of medicine.

[25]  S. Pocock,et al.  Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. , 2007, The New England journal of medicine.

[26]  Marco Valgimigli,et al.  Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[27]  P. Serruys,et al.  A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. , 2007, The New England journal of medicine.

[28]  Neville Kukreja,et al.  Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study , 2007, The Lancet.

[29]  M. Briel,et al.  Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. , 2006, European heart journal.

[30]  Anthony A Bavry,et al.  Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. , 2006, The American journal of medicine.

[31]  A. Colombo,et al.  Patterns of restenosis after drug-eluting stent implantation: Insights from a contemporary and comparative analysis of sirolimus- and paclitaxel-eluting stents. , 2006, European heart journal.

[32]  J. Tijssen,et al.  Paclitaxel-eluting versus uncoated stents in primary percutaneous coronary intervention. , 2006, The New England journal of medicine.

[33]  E. Bramucci,et al.  Sirolimus-eluting versus uncoated stents in acute myocardial infarction. , 2006, The New England journal of medicine.

[34]  B. Rensing,et al.  Primary Stenting of Totally Occluded Native Coronary Arteries II (PRISON II): A Randomized Comparison of Bare Metal Stent Implantation With Sirolimus-Eluting Stent Implantation for the Treatment of Total Coronary Occlusions , 2006, Circulation.

[35]  G. Davis,et al.  Myocardial infarction as a presentation of clinical in-stent restenosis. , 2006, Circulation journal : official journal of the Japanese Circulation Society.

[36]  Deepak L. Bhatt,et al.  Bare metal stent restenosis is not a benign clinical entity. , 2006, American heart journal.

[37]  A. Kastrati,et al.  Predictive Factors of Restenosis After Coronary Implantation of Sirolimus- or Paclitaxel-Eluting Stents , 2006, Circulation.

[38]  J. Moses,et al.  Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. , 2006, Journal of the American College of Cardiology.

[39]  H. Bøtker,et al.  The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial. , 2006, Journal of the American College of Cardiology.

[40]  F. Fernández‐Avilés,et al.  Randomized Comparison of Sirolimus-Eluting Stent Versus Standard Stent for Percutaneous Coronary Revascularization in Diabetic Patients: The Diabetes and Sirolimus-Eluting Stent (DIABETES) Trial , 2005, Circulation.

[41]  Gregg W Stone,et al.  Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. , 2005, JAMA.

[42]  Christoph Kaiser,et al.  Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET) , 2005, The Lancet.

[43]  A. Kastrati,et al.  Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. , 2005, European heart journal.

[44]  S. Silber,et al.  Two-year-plus follow-up of a paclitaxel-eluting stent in de novo coronary narrowings (TAXUS I). , 2005, The American journal of cardiology.

[45]  R. Ferrari,et al.  Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. , 2005, JAMA.

[46]  D. Simon,et al.  Molecular Basis of Restenosis and Drug-Eluting Stents , 2005, Circulation.

[47]  E. Bramucci,et al.  Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. , 2004, JAMA.

[48]  Patrick W Serruys,et al.  Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy , 2004, The Lancet.

[49]  Lawrence Joseph,et al.  A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents , 2004, The Lancet.

[50]  Gregg W Stone,et al.  One-Year Clinical Results With the Slow-Release, Polymer-Based, Paclitaxel-Eluting TAXUS Stent: The TAXUS-IV Trial , 2004, Circulation.

[51]  J. Popma,et al.  The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). , 2004, Journal of the American College of Cardiology.

[52]  Charles L. Brown,et al.  Analysis of 1-Year Clinical Outcomes in the SIRIUS Trial: A Randomized Trial of a Sirolimus-Eluting Stent Versus a Standard Stent in Patients at High Risk for Coronary Restenosis , 2004, Circulation.

[53]  G. Stone,et al.  A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. , 2004, The New England journal of medicine.

[54]  William Wijns,et al.  Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind, randomised controlled trial (E-SIRIUS) , 2003, The Lancet.

[55]  Jeffrey W Moses,et al.  Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. , 2003, The New England journal of medicine.

[56]  S. Silber,et al.  Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions , 2003, Circulation.

[57]  Mary E. Russell,et al.  TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions , 2003, Circulation.

[58]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[59]  I. Jang,et al.  Acute coronary syndrome is a common clinical presentation of in-stent restenosis. , 2002, The American journal of cardiology.

[60]  R. Choussat,et al.  In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. , 2000, Journal of the American College of Cardiology.